[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100620169":3},{"organization":4,"outcomesModule":7,"designInfo":14,"detailedDescription":20,"studyPopulation":13,"armGroups":21,"interventions":33,"overallOfficials":42,"centralContacts":50,"locations":58,"responsibleParty":79,"collaborators":13,"id":83,"slug":13,"hasResults":84,"nctId":85,"briefTitle":86,"officialTitle":87,"acronym":13,"eligibilityCriteria":88,"healthyVolunteers":84,"sex":89,"minAge":90,"maxAge":91,"enrollmentInfo":92,"targetDuration":13,"studyType":95,"phases":96,"briefSummary":98,"conditions":99,"keywords":13,"overallStatus":60,"whyStopped":13,"lastUpdateSubmitDate":101,"lastUpdatePostDateStruct":102,"startDateStruct":105,"completionDateStruct":107,"leadSponsor":109,"locationsCount":110},{"fullName":5,"class":6},"RESnTEC, Institute of Research","OTHER",{"primaryOutcomes":8,"secondaryOutcomes":13,"otherOutcomes":13},[9],{"measure":10,"description":11,"timeFrame":12},"Reduction in migraine disability","Any reduction in migraine disability score measured by PedMIDAS will be labeled as reduction (efficacy).","3 months",null,{"allocation":15,"interventionModel":16,"interventionModelDescription":13,"primaryPurpose":17,"observationalModel":13,"timePerspective":13,"maskingInfo":18},"RANDOMIZED","PARALLEL","TREATMENT",{"masking":19,"maskingDescription":13,"whoMasked":13},"NONE","Despite the clinical use of flunarizine and propranolol, direct comparisons between these two drugs in children are scarce. This study aims to bridge that gap by evaluating their relative effectiveness and safety as prophylactic treatments for pediatric migraine, addressing a critical unmet need in current research. Considering the routine use of both drugs in clinical practice, the findings would help clinicians to choose the more convenient drug between flunarizine and propranolol as preventive therapy for migraine in their local settings.",[22,28],{"label":23,"type":24,"description":25,"interventionNames":26},"Flunarizine group","EXPERIMENTAL","Patients will be receiving flunarizine beginning with 5 mg at bedtime and increasing it to 10 mg at bedtime after 1 month, over a 3-month treatment period.",[27],"Drug: Flunarizine",{"label":29,"type":24,"description":30,"interventionNames":31},"Propranolol group","Patients will be given propranolol beginning with 10 mg\u002F24 hours and increasing at the rate of 10 mg\u002Fweek to the maximum of 60 mg\u002F24 hours over a 3-month treatment period.",[32],"Drug: Propranolol",[34,38],{"type":35,"name":36,"description":25,"armGroupLabels":37,"otherNames":13},"DRUG","Flunarizine",[23],{"type":35,"name":39,"description":40,"armGroupLabels":41,"otherNames":13},"Propranolol","Patient will be given propranolol beginning with 10 mg\u002F24 hours and increase at the rate of 10 mg\u002Fweek to the maximum of 60 mg\u002F24 hour, over a 3-month treatment period.",[29],[43,47],{"name":44,"affiliation":45,"role":46},"Ishafaq Ahmed, FCPS","The Children's Hospital Lahore","PRINCIPAL_INVESTIGATOR",{"name":48,"affiliation":45,"role":49},"Muhammad Zia-ur-Rehman, FCPS","STUDY_DIRECTOR",[51,55],{"name":44,"role":52,"phone":53,"phoneExt":13,"email":54},"CONTACT","+923334957171","quaidian245ishfaq@gmail.com",{"name":48,"role":52,"phone":56,"phoneExt":13,"email":57},"+923334202863","drzia81@gmail.com",[59],{"facility":45,"status":60,"city":61,"state":62,"zip":63,"country":64,"countryCode":65,"cosmosGeoPoint":66,"geoPoint":71,"contacts":72},"RECRUITING","Lahore","Punjab Province","54600","Pakistan","PK",{"type":67,"coordinates":68},"Point",[69,70],74.35071,31.558,{"lat":70,"lon":69},[73,75,77,78],{"name":74,"role":52,"phone":53,"phoneExt":13,"email":54},"Ishfaq Ahmed, FCPS",{"name":76,"role":52,"phone":56,"phoneExt":13,"email":57},"Muhammad Zia-ur-Rehman, PCPS",{"name":74,"role":46,"phone":13,"phoneExt":13,"email":13},{"name":48,"role":46,"phone":13,"phoneExt":13,"email":13},{"type":80,"investigatorFullName":81,"investigatorTitle":82,"investigatorAffiliation":5,"oldNameTitle":13,"oldOrganization":13},"SPONSOR_INVESTIGATOR","Muhammad Aamir Latif","Research Consultant","100620169",false,"NCT07354126","Comparative Efficacy of Flunarizine and Propanolol in Pediatric Migraine","Comparative Efficacy of Flunarizine and Propanolol in Pediatric Migraine Using the PedMIDAS Measuring Tool.","Inclusion Criteria:\n\n* Children of any gender\n* Aged 8-15 years\n* Diagnosed with migraine (with\u002Fwithout aura) per International Classification of Headache Disorders, 3rd Edition (ICHD-3) criteria\n* A history of ≥4 migraine attacks\u002Fmonth for the preceding 3 months\n* With a PedMIDAS score ≥11 (moderate-to-severe impact)\n\nExclusion Criteria:\n\n* Children with secondary headache disorders (e.g., due to infections, trauma, structural brain lesions)\n* Known hypersensitivity or contraindications to flunarizine or propranolol\n* Presence of cardiovascular disorders (e.g., bradycardia, heart block, hypotension, asthma)\n* Non-compliance or inability to attend regular follow-ups\n* Participation in another clinical trial within the last 3 months","ALL","8 Years","15 Years",{"count":93,"type":94},44,"ESTIMATED","INTERVENTIONAL",[97],"NA","Flunarizine and propranolol have demonstrated efficacy in reducing migraine frequency across age groups, though evidence in pediatric populations remains limited and inconsistent. Therefore, the current study has been planned to evaluate and compare the effectiveness of flunarizine and propranolol in reducing migraine frequency in children aged 8-15 using the Pediatric Migraine Disability Assessment Scale (PedMIDAS) score.",[100],"Migraine","2026-01-12",{"date":103,"type":104},"2026-01-21","ACTUAL",{"date":106,"type":104},"2025-09-01",{"date":108,"type":94},"2026-02-28",{"name":81,"class":6},1]